Natera,Inc. (NASDAQ:NTRA) Files An 8-K Regulation FD Disclosure

ME Staff 8-k

6 years ago

Natera,Inc. (NASDAQ:NTRA) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.

On June27, 2018, Natera,Inc. (“Natera”) will hold an investor call to discuss study data and its strategic roadmap for its emerging businesses in organ transplantation and oncology, and will provide a related investor presentation. A copy of the investor presentation is furnished herewith as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.

The information in this Current Report on Form8-K and the accompanying Exhibit99.1 shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

ExhibitNo.	Description
99.1	Investor Presentation.

EXHIBITINDEX

ExhibitNo.	Description
99.1	Investor Presentation.

Natera, Inc. ExhibitEX-99.1 2 a18-16102_1ex99d1.htm EX-99.1 Exhibit 99.1 Natera,…To view the full exhibit click here
About Natera,Inc. (NASDAQ:NTRA)
Natera, Inc. is a diagnostics company. The Company’s product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother’s blood and a blood sample from the alleged father(s).